{"id":"W3189278449","doi":"10.1016/j.eururo.2021.07.019","title":"Adjuvant Immune Checkpoint Inhibition in Muscle-invasive Bladder Cancer: Is It Ready for Prime Time?","year":2021,"lang":"en","type":"editorial","venue":"European Urology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"ca_institutions":"McGill University Health Centre; Queen's University","funders":"","keywords":"Medicine; Atezolizumab; Nivolumab; Bladder cancer; Adjuvant; Oncology; Internal medicine; Chemotherapy; Neoadjuvant therapy; Immunotherapy; Adjuvant chemotherapy; Cancer; Urology; Breast cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008727562,0.003007714,0.004861824,0.002070847,0.001955614,0.005494405,0.003467333,0.01647472,0.009158465],"category_scores_gemma":[0.01811726,0.001062024,0.003205944,0.001266934,0.001626244,0.004174171,0.0011746,0.02450929,0.006500268],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.003066512,"about_ca_system_score_gemma":0.00369249,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001919004,"about_ca_topic_score_gemma":0.005406095,"domain_scores_codex":[0.9962843,0.000860133,0.0005359221,0.0004095884,0.001601284,0.0003087762],"domain_scores_gemma":[0.9844589,0.007481833,0.0009904811,0.0002595604,0.004315692,0.00249353],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001348756,0.00002474235,0.00002417622,0.0006173553,0.00005277577,0.00007915957,0.000008131211,0.00003260112,0.00006551941,0.0002723529,0.986414,0.01227421],"study_design_scores_gemma":[0.0004716179,0.0002201288,0.0005013007,0.0015012,0.0003258677,0.0003536596,0.0000395287,0.0002853243,0.0001550878,0.001393211,0.9947091,0.00004399789],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"editorial","genre_gemma":"editorial","genre_scores_codex":[0.00004496205,0.0302422,0.0001255184,0.04200695,0.9260276,0.00002574825,0.0000598667,0.00004367537,0.001423553],"genre_scores_gemma":[0.0004798875,0.01779582,0.000100728,0.03193461,0.9448826,0.00002848959,0.0000416111,0.00002160632,0.004714697],"genre_candidate":"editorial","genre_consensus":"editorial","teacher_disagreement_score":0.01647472,"threshold_uncertainty_score":0.04615635,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02389745304614387,"score_gpt":0.3051402551644497,"score_spread":0.2812428021183058,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}